Literature DB >> 2667814

Scaling facial impairment.

J M Tobiasen1.   

Abstract

A major goal of the treatment of cleft lip and palate is to improve the esthetic acceptability of the face. It is assumed that an improved esthetic appearance is associated with significant psychosocial benefits, but there is almost no empiric support for this assumption. Researchers have been hindered in the study of this problem because scales to measure severity of facial impairment of clefts have not been available; however, standard scales of facial impairment have been developed for occlusal traits, orthognathic structure, and facial attractiveness. The purpose of this paper is to describe selected theoretic and methodologic approaches to scaling the esthetic acceptability of various facial characteristics and to discuss how these methods have been applied to the study of relationships between facial morphology and psychosocial variables. It is argued that these approaches may be useful, as models for the development of scales of severity of cleft impairment, to clinicians and researchers who are interested in the treatment of facial clefts.

Entities:  

Mesh:

Year:  1989        PMID: 2667814

Source DB:  PubMed          Journal:  Cleft Palate J        ISSN: 0009-8701


  3 in total

1.  Objective three-dimensional assessment of lip form in patients with repaired cleft lip.

Authors:  Chihiro Tanikawa; Kenji Takada; John van Aalst; Carroll Ann Trotman
Journal:  Cleft Palate Craniofac J       Date:  2010-03-12

2.  Surgeon's and Caregivers' Appraisals of Primary Cleft Lip Treatment with and without Nasoalveolar Molding: A Prospective Multicenter Pilot Study.

Authors:  Hillary L Broder; Roberto L Flores; Sean Clouston; Richard E Kirschner; Judah S Garfinkle; Lacey Sischo; Ceib Phillips
Journal:  Plast Reconstr Surg       Date:  2016-03       Impact factor: 4.730

Review 3.  Treatment outcomes of pre-surgical infant orthopedics in patients with non-syndromic cleft lip and/or palate: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Hamid Reza Hosseini; Eleftherios G Kaklamanos; Athanasios E Athanasiou
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.